Neuroscience startup BrainSight AI raises $5 million in funding

Neuroscience startup BrainSight AI has raised $5 million in a pre-Series A funding round led by IAN Alpha Fund, with participation from IvyCap Ventures, Silver Needle, and existing investors.

The Bengaluru-based startup, which previously secured $925,000 from Pfizer and others, plans to use the new capital to expand across Tier I and Tier II cities in India, venture into Africa and Southeast Asia, and pursue U.S. market entry through FDA certification.

A portion of the funds will also support research and development, including new solutions for patient and caregiver needs.

What does BrainSight AI do?

Founded in 2019 by CEO and ISB graduate, Laina Emmanuel, and CTO and NIMHANS PhD, Rimjhim Agrawal, BrainSight AI combines artificial intelligence and neuroscience to diagnose and treat brain disorders with greater precision.

Its primary products include Voxelbox, an fMRI processing engine enhanced by machine learning, and Snowdrop, a patient-care app designed to help patients stay on track with treatment regimens.

Partnership with more than 40 hospitals

Currently, the startup collaborates with more than 40 hospitals across India to assist in neurosurgery and radiology, particularly in cases of brain tumors.

By mapping neural connections in the brain, the platform offers insights that empower doctors to plan safer, more targeted surgeries and, increasingly, to treat a wider range of neurological and psychiatric conditions.

With the goal of democratizing advanced brain care once limited to prestigious institutions like Harvard and Stanford, BrainSight AI’s founders envision their technology reaching hospitals and patients worldwide.

The company hopes to triple its existing user base and drive broader awareness of connectomics—the study of brain networks—as a powerful tool in personalized care.

Emmanuel has described this approach as potentially transformative, enabling doctors to identify and navigate critical brain functions before performing surgeries.

With plans for caregiver-focused apps, an enhanced R&D pipeline, and expanded global operations, BrainSight AI aims to shape the future of neuro-oncological and neuropsychiatric diagnosis.